Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.
Lehtinen M, Gray P, Luostarinen T, Eriksson T, Apter D, Bly A, Harjula K, Heikkilä K, Hokkanen M, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pimenoff VN, Pukkala E, Dillner J. Lehtinen M, et al. Among authors: harjula k. Front Cell Infect Microbiol. 2024 Sep 9;14:1437704. doi: 10.3389/fcimb.2024.1437704. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39315334 Free PMC article. Clinical Trial.
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J. Lehtinen M, et al. Among authors: harjula k. BMJ Open. 2017 Aug 18;7(8):e015867. doi: 10.1136/bmjopen-2017-015867. BMJ Open. 2017. PMID: 28821519 Free PMC article. Clinical Trial.
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Bly A, Gray P, Harjula K, Heikkilä K, Hokkanen M, Karttunen H, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pukkala E, Soderlund-Strand A, Veivo U, Dillner J. Lehtinen M, et al. Among authors: harjula k. BMJ Open. 2021 Dec 30;11(12):e050669. doi: 10.1136/bmjopen-2021-050669. BMJ Open. 2021. PMID: 35149535 Free PMC article. Clinical Trial.
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Dillner J, Dubin G, Garnett G. Lehtinen M, et al. Among authors: harjula k. Int J Cancer. 2018 Mar 1;142(5):949-958. doi: 10.1002/ijc.31119. Epub 2017 Nov 9. Int J Cancer. 2018. PMID: 29055031 Clinical Trial.
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, Garnett G. Lehtinen M, et al. Among authors: harjula k. Int J Cancer. 2018 Nov 1;143(9):2299-2310. doi: 10.1002/ijc.31618. Epub 2018 Aug 10. Int J Cancer. 2018. PMID: 29845626
Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, Harjula K, Heikkilä K, Hokkanen M, Huhtinen L, Ikonen M, Karttunen H, Nummela M, Söderlund-Strand A, Veivo U, Dillner J, Elfstöm M, Nieminen P, Lehtinen M. Louvanto K, et al. Among authors: harjula k. Int J Cancer. 2020 Jul 15;147(2):440-447. doi: 10.1002/ijc.32802. Epub 2019 Dec 16. Int J Cancer. 2020. PMID: 31749143 Clinical Trial.
Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland.
Lehtinen M, Apter D, Eriksson T, Harjula K, Hokkanen M, Natunen K, Nieminen P, Paavonen J, Palmroth J, Petäjä T, Pukkala E, Vänskä S, Cheuvart B, Soila M, Bi D, Struyf F. Lehtinen M, et al. Among authors: harjula k. Cancer Med. 2021 Nov;10(21):7759-7771. doi: 10.1002/cam4.4299. Epub 2021 Sep 27. Cancer Med. 2021. PMID: 34581025 Free PMC article. Clinical Trial.
The quality of life of frequently vs. infrequently screened HPV vaccinated women.
Taavela K, Eriksson T, Huhtala H, Bly A, Harjula K, Heikkilä K, Hokkanen M, Nummela M, Kotaniemi-Talonen L, Lehtinen M, Louvanto K. Taavela K, et al. Among authors: harjula k. Qual Life Res. 2024 Apr;33(4):941-949. doi: 10.1007/s11136-023-03575-y. Epub 2024 Jan 18. Qual Life Res. 2024. PMID: 38238599 Free PMC article. Clinical Trial.
Impact of HPV16/18 vaccination on quality of life: a pilot study.
Eriksson T, Torvinen S, Woodhall SC, Lehtinen M, Apter D, Harjula K, Hokkanen M, Rissanen P, Paavonen J, Lehtinen M. Eriksson T, et al. Among authors: harjula k. Eur J Contracept Reprod Health Care. 2013 Oct;18(5):364-71. doi: 10.3109/13625187.2013.801953. Epub 2013 Jun 17. Eur J Contracept Reprod Health Care. 2013. PMID: 23768267 Clinical Trial.
15 results